biotech · Huntington Disease · Alzheimer Disease · VYGR
Voyager Therapeutics
Voyager Therapeutics is a biotech organization headquartered in Lexington, USA. It trades on NYSE under ticker VYGR. Primary therapeutic focus areas include Huntington Disease, Alzheimer Disease, Alzheimer's Disease, Alz
Lexington, USA HQ
2014 Founded
168 Employees
Public company Type
VYGR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lexington, USA
- Founded
- 2014
- Employees
- 168
- Programs
- 4
- Drugs
- 4
- Patents
- 31
Leuprolide acetate
Phase 2 · small molecule · Alzheimer Disease
Leuprolide acetate for Alzheimer Disease is a Phase 2 program (small_molecule) at Voyager Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code IA0047
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Voyager Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alzheimer Disease
- Status
- completed
- Trials
- 2